Buscar resultados de ensayos clínicos
Chromosome 5q Deletion - 10 Studies Found
Estado | Estudiar |
Terminated |
Nombre del estudio: Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome Condición: Myelodysplastic Syndrome (MDS) Fecha: 2011-08-18 Intervenciones: Drug: ezatiostat hydrochloride (Telintra®) Three weeks of treatment with ezatiostat at 2000 mg per |
Completed |
Nombre del estudio: Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia Condición: Myelodysplastic Syndrome (MDS) Fecha: 2011-04-13 Intervenciones: Drug: Azacitidine Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be a |
Completed |
Nombre del estudio: Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality Condición: Myelodysplastic Syndromes Fecha: 2005-09-10 Intervenciones:
|
Completed |
Nombre del estudio: Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q Condición: Myelodysplastic Syndromes Fecha: 2010-03-02 Intervenciones: Drug: Lenalidomide 10 mg d1-d21 of a 28-day cycle Ot |
Terminated |
Nombre del estudio: Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS) Condición: Leukemia Fecha: 2010-10-14 Intervenciones:
|
Completed |
Nombre del estudio: Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Condición:
|
Recruiting |
Nombre del estudio: Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome Condición: Myelodysplastic Syndrome Fecha: 2010-11-17 Intervenciones:
|
Completed |
Nombre del estudio: MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry Condición: Myelodysplastic Syndrome Fecha: 2010-10-29 Intervenciones: Drug: lenalidomide Patients who were prescribed Revlimid from 31October 2008 to present. |
Completed |
Nombre del estudio: A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q Condición:
|